|1.||Zwarthoff, Ellen C: 12 articles (07/2013 - 12/2002)|
|2.||van Rhijn, Bas W G: 8 articles (08/2014 - 12/2002)|
|3.||Legeai-Mallet, Laurence: 8 articles (12/2012 - 07/2006)|
|4.||Radvanyi, François: 7 articles (10/2013 - 01/2003)|
|5.||Hristova, Kalina: 7 articles (01/2013 - 02/2006)|
|6.||Munnich, Arnold: 7 articles (12/2012 - 07/2006)|
|7.||Stewart, A Keith: 6 articles (10/2015 - 07/2003)|
|8.||van der Kwast, Theo H: 6 articles (08/2014 - 01/2003)|
|9.||Trudel, Suzanne: 6 articles (11/2006 - 03/2004)|
|10.||Krejci, Pavel: 5 articles (01/2016 - 06/2009)|
06/01/2002 - "[corrected] To investigate the mutation at the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) nucleotide 1138 site for identifying the major pathologic mechanism of achondroplasia (ACH) and to evaluate the efficacy of denaturing gradient gel electrophoresis(DGGE) method for screening the point mutations. "
11/01/1998 - "Recent studies of the fibroblast growth factor receptor 3 (FGFR3) gene have established that achondroplasia and hypochondroplasia are allelic disorders of different mutations. "
01/02/1995 - "Recent studies mapped the achondroplasia gene on chromosome region 4p16.3 and identified a common mutation in the gene encoding the fibroblast growth factor receptor 3 (FGFR3). "
03/01/2015 - "The most common achondroplasia mutation, p.Gly380Arg in fibroblast growth factor receptor 3 (FGFR3), was detected in both patients. "
01/01/2014 - "Achondroplasia is caused, in virtually all of the cases, by a G380R mutation in fibroblast growth factor receptor 3 (FGFR3). "
05/15/2003 - "Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome."
01/01/2016 - "Enhanced Expression of Fibroblast Growth Factor Receptor 3 IIIc Promotes Human Esophageal Carcinoma Cell Proliferation."
05/01/2015 - "Urothelial carcinoma of the bladder in patients aged 30 years or younger: clinicopathological analysis and expression of fibroblast growth factor receptor 3 (FGFR3) of 45 cases."
01/01/2014 - "Alterations in fibroblast growth factor receptor 3 (FGFR3) have been implicated in the pathogenesis of urothelial carcinoma. "
07/01/2011 - "The human fibroblast growth factor receptor 3 (FGFR3) gene is frequently mutated in superficial urothelial cell carcinoma (UCC). "
|3.||Urinary Bladder Neoplasms (Bladder Cancer)
09/01/2005 - "Previous gene expression studies have shown that fibroblast growth factor receptor 3 (FGFR3) is overexpressed in early stages of bladder cancer. "
04/09/2015 - "Fibroblast Growth Factor Receptor 3 (FGF-R3): A Promising Therapeutic Target for the Treatment of Bladder Cancer."
07/01/2013 - "Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer."
05/01/2013 - "Several genetic changes may occur in bladder cancer, but activating mutations in the fibroblast growth factor receptor 3 (FGFR3) genes are the most common and most specific genetic abnormality in bladder cancer. "
05/01/2013 - "Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer."
|4.||Thanatophoric Dysplasia (Dwarfism, Thanatophoric)
09/01/2013 - "Thanatophoric dysplasia (TD) and hypochondroplasia are both caused by FGFR3 (fibroblast growth factor receptor 3) gene mutations. "
05/01/2012 - "Fetal thanatophoric dysplasia is a lethal skeletal dysplasia due to mutation of fibroblast growth factor receptor 3 gene. "
01/01/2010 - "Nucleotidic sequence using QF-PCR on exons 7,10, 15, 19 of the fibroblast growth factor receptor 3 (FGFR3) demonstrated a 742 C>T (R248C) mutation, which resulted in an Arg248Cys substitution in heterozygous state, leading to a prenatal diagnosis of thanatophoric dysplasia type I. The early diagnosis of this lethal form of skeletal dysplasia directed the prenatal counseling and allowed appropriate obstetric management. "
06/01/2009 - "Thanatophoric dysplasia is a lethal chondrodysplasia caused by heterozygous fibroblast growth factor receptor 3 (FGFR3) missense mutations. "
06/01/2007 - "Recurrent missense fibroblast growth factor receptor 3 (FGFR3) mutations have been ascribed to skeletal dysplasias of variable severity including the lethal neonatal thanatophoric dysplasia types I (TDI) and II (TDII). "
03/01/2004 - "Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma."
01/01/2014 - "The t(4; 14) translocation leads to the simultaneous overexpression of two genes, FGFR3 (fibroblast growth factor receptor 3) and MMSET (multiple myeloma SET domain), both of which have potential oncogenic activity. "
09/01/2011 - "Fibroblast growth factor receptor 3 (FGFR3) is up-regulated as a result of the t(4;14)(p16;q32) translocation that occurs in up to 20% of multiple myeloma (MM) patients. "
01/01/2011 - "The ectopically expressed fibroblast growth factor receptor 3 (FGFR3) and its constitutively active mutations have been detected in patients with multiple myeloma (MM). "
07/15/2010 - "Reciprocal IGH/14q32 translocations are detectable in 55-70% of patients with plasma cell myeloma; e.g., the adverse t(4;14)(p16;q32) fusing the IGH and FGFR3 genes (immunoglobulin heavy chain/fibroblast growth factor receptor 3). "
|1.||Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Messenger RNA (mRNA)
|7.||Telomerase (Telomerase Reverse Transcriptase)
|9.||Catalytic RNA (Ribozymes)
|10.||nuclear matrix protein 22
|2.||Heterologous Transplantation (Xenotransplantation)